Patients’ Bill of Rights Good News Either Way

Publication
Article
OncologyONCOLOGY Vol 15 No 9
Volume 15
Issue 9

With House passage of the Ganske bill (H.R. 526, introduced by Rep. Greg Ganske, R-IA), it is now certain that there will

With House passage of the Ganske bill (H.R. 526, introduced by Rep. Greg Ganske,R-IA), it is now certain that there will be a strong clinical trials provision in any managed-care reform bill that emergesfrom Congress—that is, if one emerges. 

When the House passed the Ganske billin early August, it added an amendment that eliminated provisions on the filingof lawsuits and substituted provisions developed by Rep. Charlie Norwood (R-GA)and President George W. Bush. The Norwood amendment limits the kinds of lawsuitspatients can file in state court and caps the damages they can receive fromthose suits. 

The Norwood provision differs from the lawsuit provision in aSenate bill, which Senate Democrats are insisting on retaining in anymanaged-care bill passed by a House-Senate conference committee. 

Julie Taylor,deputy director of public policy at the American Society of Clinical Oncology (ASCO),said that ASCO has not taken a position on the lawsuit provisions, restrictingits comments to provisions that specifically affect cancer care. 

To the extentthat a final bill—again, if there is a final bill—will contain a provisionrequiring payment of routine patient care costs in clinical trials (whetherfederally or privately funded), ASCO couldn’t be happier.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content